For Better User Experience Please Use Potrait Mode.
CanAssist-Breast is a 5 biomarker morphometric IHC test that will help to determine your cancer’s risk of recurrence. You will get a result that classifies your disease as either low- or high-risk for recurrence. A low-risk of recurrence means your cancer has 0 to 9% (average 4.5%) chance of recurring within 5 years. A high risk of recurrence means your cancer has a >10% chance of coming back within 5 years. These results are not a guarantee that your cancer will or will not recur, but will provide valuable information to your doctors which will help them design a customized treatment plan for you.
The report will be dispatched within 10 working days.
All women with <74 years of age with Hormone Receptor (ER/PR) positive Invasive Ductal / Lobular Carcinoma of the Breast, whether node negative or node positive, and Her2 negative can use CanAssist-Breast to determine their risk of recurrence.
CanAssist-Breast can only be ordered upon the recommendation by a treating clinician. You may ask your doctor to run the CanAssist-Breast test on your Breast Cancer sample. For more information on ordering CanAssist-Breast please see the Test Requisition Form or contact the OncoStem team at
CanAssist-Breast is performed on FFPE tumor blocks from lumpectomy, Mastectomy or Breast Conserving surgery specimens. A 30% tumor content in the block is minimally required to carry out the test.
CanAssist-Breast test is performed at OncoStem’s central laboratory in Bangalore, India.
Ramkumar C, Prakash C, Madhav L, Kumar A, Basavaraj C, et al. (2017) Assessment of Ki67 As a Prognostic Marker in Hormone Receptor Positive Breast Cancer: A Retrospective Study on An Indian Cohort. J Mol Biomark Diagn 8: 336.
Somashekhar, S., Bakre, M. M., Ramkumar, C., Basavaraj, C., Arun Kumar, A., et al. (2017). 1675PRisk of recurrence prediction and optimum treatment planning for early stage breast cancer patients: A cost-effective, accurate and broad based solution for Asia. Annals of Oncology, 28(suppl_5).
Clinical development and validation of a morphometric IHC test to predict risk of recurrence in patients with early-stage ER/PR+ Invasive Ductal Carcinoma of Breast (manuscript under preparation).
Analytical Validation of the lmmunohistochemistry-based CanAssist-Breast Prognostic Test for Prediction of Risk of Recurrence in Hormone Receptor- Positive Breast Cancer (manuscript under review).
Prakash C., Aparna Gunda, Arun Kumar Attuluri et al. (2018) Risk stratification in early-stage estrogen receptor+/HER2-breast cancer patients: Comparative analysis of cost-effective methods. J Curr Oncol, 1: 1, 5-15.
CoBrCa 2016, Spain - 2nd World Congress on Controversies in Breast Cancer. Oral presentation on CanAssist-Breast by Dr. Manjiri Bakre
OncoStem Diagnostics was selected by KBITS to participate in BioKorea 2016. OncoStem Diagnostics was part of the KBITS delegation of 7 selected start-ups that showcased their technologies in the BioKorea tradeshow and conference.
Asia Pacific Breast Cancer Symposium (APSCS) 2017, Hong Kong. CanAssist-Breast abstract was selected for poster presentation
ESMO 2017 (European Society for Medical Oncology Congress), Spain. Poster presentation on “Risk of recurrence prediction and optimum treatment planning for early stage breast cancer patients: A cost-effective, accurate and broad based solution for Asia”.
Indian Cancer Congress (ICC) 2017, Bangalore, India. CanAssist-Breast abstract was selected for poster presentation. Dr. Manjiri Bakre was an invited panellist.
San Antonio Breast Cancer Symposium® 2017 (SABCS®), USA. Poster presentation on “Development and validation of a broad-based second generation multi marker Morphometric IHC test for optimal treatment planning of stage 1 and 2 breast cancer patients in low resource settings”
Global Breast Cancer Conference (GBCC) 2018, South Korea. Dr. Manjiri Bakre was invited to give a talk on CanAssist-Breast as one of 10 winners of the KBCF International Scholarship.
CanAssist-Breast: Innovative test for prediction of risk of recurrence, Beyond ER, PR and Her2. International Cancer Congress, 9-10th July 2016, Nagpur.
Development and validation of IHC based test for prediction of risk of recurrence for breast cancer patients: Beyond ER, PR and Her2. Advanced Diagnostics, 27-28th May 2016, Bangalore.
Development of IHC based test for prediction of risk of recurrence for breast cancer patients. Indian Association of Cancer Research 2015, Jaipur.
A novel diagnostic test to predict risk of recurrence in Breast Cancer”, Scientific presentation at Global Cancer Summit, Bangalore, 2015.
Trends in Biomarker discovery in cancer: The devil is in molecular pathways. Invited Speaker, Emerging Technologies Session. Indian Cancer Congress, November 2013, New Delhi.